Credits Available: 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC

Description: Welcome to our comprehensive learning program on screening, diagnosing, and managing IgA nephropathy (IgAN). This program aims to provide you with a deep understanding of screening techniques, referral procedures, treatment selection, drug distribution and safety and monitoring requirements in IgAN management. Furthermore, this activity encourages care coordination between interdisciplinary team members to improve the co-management of patients with IgAN.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Physician Associate/Assistant, Pharmacist
Target Specialties: Nephrology, Family Medicine, Pharmacy

Dana Rizk

University of Alabama at Birmingham

Dr Dana Rizk is Tenured Professor of Medicine in the Division of Nephrology and Associate Dean for Clinical Trials at the University of Alabama at Birmingham (UAB) Heersink School of Medicine. Her clinical and research interests revolve around rare glomerular diseases and, in particular IgA Nephropathy (IgAN). She has served as the site principal investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in the diagnosis and prognosis of IgAN. Her research efforts have resulted in more than 80 peer-reviewed publications in prestigious medical journals including the New England Journal of Medicine.